EOS 215
Alternative Names: EOS-006215; EOS-215Latest Information Update: 23 Jun 2025
At a glance
- Originator iTeos Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TREM2 protein-inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 Apr 2025 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT06877533)
- 07 Apr 2025 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Monotherapy, Inoperable/Unresectable) in USA (Parenteral) (NCT06877533)